Characteristic

Pulsar

Spectra

Stellar

Zenith

Study design

Phase 2 RCT

Phase 2a open-label

Phase 3 RCT

Phase 3 RCT

Number of patients

106

~ 21

~ 323

Not specified

WHO functional class

II-III

III

II-III

III-IV (high-risk)

Background therapy

Yes

Yes

Yes

Yes

Treatment duration

24 weeks

Not specified

24 weeks

~ 10.6 months (median)

Dosing

0.3 mg/kg or 0.7 mg/kg SC q3w

Not specified

Not specified

Not specified